The Rage to Consolidate in Diagnostics

As diagnostic industry infrastructure and R&D costs escalate and buyers gain more clout, manufacturers are looking to consolidation for long-term viability and growth. Faster growth is the motivation for market leaders, while size and operating efficiencies are driving other deals.

In January of this year, the national hospital alliance Premier Inc. announced the winners of its contract for clinical chemistry. The contract had been particularly important because it would cover all of Premier's 1,800 member hospitals, or about a third of hospitals in the US. Moreover, only one chemistry company would win—so bidders cut prices to the bone, figuring to make their money back on volume. But instead of choosing one supplier, Premier chose three, giving it the best of both worlds—heavy discounts and a choice of vendors.

Upset over the process and the pricing, each of the three winners, Johnson & Johnson Clinical Diagnostics, Corange Ltd.subsidiary Boehringer...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business Strategy

More from In Vivo

Deals In Depth: June 2025

 
• By 

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By 

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By 

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.